Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways

INTRODUCTION: Sunitinib is the first-line targeted drug for the treatment of advanced renal cell carcinoma (RCC), but its therapeutic potential is limited by premature drug resistance. In an attempt to overcome this limitation, a sunitinib-resistant cell-derived xenograft (CDX) model of clear cell r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yingwei, Shangguan, Wentai, Chen, Zhiliang, Zheng, Zaosong, Chen, Yuqing, Zhong, Qiyu, Zhang, Yishan, Yang, Jingying, Zhu, Dingjun, Xie, Wenlian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687523/
https://www.ncbi.nlm.nih.gov/pubmed/34938069
http://dx.doi.org/10.2147/DDDT.S343718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687523/
https://www.ncbi.nlm.nih.gov/pubmed/34938069
http://dx.doi.org/10.2147/DDDT.S343718

Ejemplares similares